II Ivivi Technologies, Inc.

Ivivi Technologies, Inc. (AMEX:II), an innovator of non-invasive, electrotherapeutic technology, today commented on the recent American Heart Association�s (AHA) Scientific Statement, published in Circulation: Journal of the American Heart Association, recommending that due to increased risk of heart attack and stroke, physicians should avoid prescribing non-steroidal anti-inflammatory drugs (NSAIDs) to patients at risk for, or with, heart disease, unless other non-pharmacological treatments have failed to produce the desired clinical result. Andre� DiMino, Vice Chairman and Co-Chief Executive Officer, stated, �AHA�s guideline should serve as a �call to action� for physicians and the medical community, encouraging further exploration of the benefits of non-pharmacological therapies to reduce chronic pain. We intend to initiate a working relationship with the AHA to ensure that its member physicians and other healthcare professionals are aware of the benefits of Ivivi�s Electroceuticals� and how they could be useful in light of the AHA�s guideline to use non-pharmacological therapies whenever possible.� Great strides have been made over the past several years in elucidating the mechanisms of action of pulsed electromagnetic field, or PEMF. This technology, which creates non-thermal electrical current in injured soft tissue, is specifically configured to augment the biochemical and physiological processes used by the human body to reduce pain and edema in its natural quest for tissue repair. The Company�s proprietary PEMF signals, which are referred to as Electroceuticals�, are delivered by devices which have been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative pain and edema in soft tissue. These devices have been used in over 600,000 non-invasive applications for the treatment of pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders, including chronic wounds. The therapy is non-toxic and has no known side effects. �The positive benefits of electromagnetic modulation of the body�s own electrochemical physiology have been demonstrated in animal and human clinical studies for the treatment of recalcitrant fractures and chronic wounds. PEMF efficacy has also been demonstrated for increased growth of blood vessels and reduction of pain and swelling after surgical procedures, and shows great promise as an alternative to NSAIDs for the relief of chronic and acute pain,� said Dr. Arthur A. Pilla, Professor of Biomedical Engineering, Columbia University, Science Director and Chairman of the Scientific Advisory Board, Ivivi Technologies, Inc., and inventor of the first PEMF bone growth stimulator which was FDA-cleared for recalcitrant fracture repair. �Ivivi believes the world of medicine is on the verge of exploiting the relationship between the body�s electrochemistry and healing. Electrotherapeutics has been shown to be inherently safer than many drugs, which Ivivi believes creates a natural advantage for patients, healthcare professionals and even insurers. Certainly, the use of PEMF technology in orthopedics has resulted in significant reductions in morbidity and the cost of health care for these indications since 1980.� In its Scientific Statement, the AHA has specifically stated that some NSAIDs, including ibuprofen and cox2 inhibitors, increase the risk of heart failure, stroke, hypertension and gastrointestinal bleeding in some patients. Additional information on the AHA Scientific Statement can be found at http://www.americanheart.org/presenter.jhtml?identifier=3045689. About Ivivi Technologies, Inc. Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi�s research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company�s Electroceuticals� have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders. Forward-Looking Statements This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company�s limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company�s products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company�s intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company�s products and other risks detailed from time to time in the Company�s filings with the Securities and Exchange Commission, including the Company�s registration statement on Form SB-2. The Company assumes no obligation to update the information contained in this press release.